quinuclidine

Cevimeline hydrochloride hemihydrate is a novel muscarinic receptor agonist, used as a candidate therapeutic drug for xerostomia in Sjogren's syndrome.

(R)-3-aminoquinuclidine dihydrochloride ,with CAS No. 123536-14-1, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. (R)-3-aminoquinuclidine dihydrochloride provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

3-Hydroxyquinuclidine-3-carbonitrile hydrochloride ,with CAS No. 706811-54-3, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. 3-Hydroxyquinuclidine-3-carbonitrile hydrochloride provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Aceclidine (1-azabicyclo[2.2.2]octan-3-yl acetate) is a modulator of M3 mAChR and can be used in studies about treating glaucoma by reducing intraocular pressure.

(S)-Quinuclidin-3-amine dihydrochloride is a biochemical reagent that can be used as a biomaterial for life science related research and as a sulfonylation reagent for organic synthesis and drug discovery.

Solifenacin succinate (YM905) is a quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.

The quinuclidine PHA 568487 free base is an agonist of the alpha 7 nicotinic acetylcholine receptor that was designed to mitigate the bioactivation associated with the core scaffold and subsequently remove associated liabilities with in vivo tolerability.

Cevimeline hydrochloride (AF102B hydrochloride) is a quinuclidine derivative of acetylcholine that functions as a selective, orally active muscarinic M1 and M3 receptor agonist. Cevimeline hydrochloride effectively stimulating exocrine secretion from salivary glands and thereby serving as a clinically relevant sialogogue for the treatment of xerostomia, while its demonstrated ability to cross the blood–brain barrier supports its utility in central and peripheral cholinergic signaling studies and translational neuropharmacological investigations.